




# WDL AP News

## WDL Immunohistochemistry onboards novel sarcoma markers




With July being sarcoma awareness month, coincidentally the IHC department within WDL has recently introduced two new stains that are game changers for making accurate sarcoma diagnoses. SS18-SSX is a gene fusion that occurs in synovial sarcomas. WDL has introduced an assay that detects this specific gene fusion and enables a quick diagnosis and sub-classification of synovial sarcomas without having to wait for send-out genetic testing.

SS18-SSX  
immunohistochemistry  
stain on synovial  
sarcoma

---

Additionally, WDL IHC has also introduced another valuable marker helpful for sub-classifying sarcomas, NKX2.2. For years, CD99 has been the gold standard in the differential diagnosis for Ewing sarcoma. This is, however, not without its pitfalls. While CD99 is a very sensitive marker for Ewing sarcoma, it is not extremely specific. Even though CD99 almost always stains Ewing's cases, it stains a lot of other disease states as well. This is where NKX2.2 comes in. NKX2.2 will only stain Ewing sarcoma cases within the common differential diagnoses for which Ewing sarcoma is included. This gives the pathologist an assay with superior sensitivity and specificity to diagnose Ewing sarcoma faster and more accurately than ever before.



NKX2.2 IHC on Ewing Sarcoma.